Bausch Health (BHC) and its aesthetics business, Solta Medical, announced Fraxel FTX will launch at the American Society for Laser Medicine & Surgery 2025 Annual Conference on April 25 in Orlando, FL. This event begins the rollout of Fraxel FTX to dermatologists, plastic surgeons, and other licensed aesthetic professionals across the United States, with plans to expand globally in the coming months. Fraxel is a treatment in skin rejuvenation, addressing common skin concerns such as sun damage, wrinkles, acne scars, and pigmentation irregularities. The company said, “With the introduction of Fraxel FTX, the next generation of skin resurfacing technology, Bausch Health is setting a new standard in laser skin resurfacing. Designed to offer an even more precise, efficient, and comfortable treatment experience, this next generation product provides dermatologists and aesthetic professionals with advanced tools and is designed to deliver noticeable results after a single treatment in all skin types.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health Addresses Icahn’s Equity Swaps and Adopts Shareholder Rights Plan
- Bausch Health announces filing of supplement to proxy statement
- Bausch Health price target lowered to $5 from $7 at BofA
- U.S. District Court Rules in Favor of Bausch Health and FDA in XIFAXAN Case
- Bausch says court grants summary judgment in favor of FDA, Salix, and Teva